These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 21302806)

  • 1. Cancer: a novel "no-nonsense" approach to treatment.
    Loudon JA
    Oncol Res; 2010; 19(2):55-66. PubMed ID: 21302806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer syndromes and therapy by stop-codon readthrough.
    Bordeira-Carriço R; Pêgo AP; Santos M; Oliveira C
    Trends Mol Med; 2012 Nov; 18(11):667-78. PubMed ID: 23044248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sense from nonsense: therapies for premature stop codon diseases.
    Bidou L; Allamand V; Rousset JP; Namy O
    Trends Mol Med; 2012 Nov; 18(11):679-88. PubMed ID: 23083810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical therapies to recode nonsense mutations in inherited diseases.
    Lee HL; Dougherty JP
    Pharmacol Ther; 2012 Nov; 136(2):227-66. PubMed ID: 22820013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeutic readthrough strategy for suppression of nonsense mutations in duchenne muscular dystrophy].
    Shiozuka M; Matsuda R
    Brain Nerve; 2011 Nov; 63(11):1253-60. PubMed ID: 22068478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The functional mechanisms and clinical application of read-through drugs.
    Fu Y; Shu ZY; Gu MM
    Yi Chuan; 2016 Jul; 38(7):623-633. PubMed ID: 27733335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational read-through as an alternative approach for ocular gene therapy of retinal dystrophies caused by in-frame nonsense mutations.
    Nagel-Wolfrum K; Möller F; Penner I; Wolfrum U
    Vis Neurosci; 2014 Sep; 31(4-5):309-16. PubMed ID: 24912600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells.
    Bidou L; Bugaud O; Belakhov V; Baasov T; Namy O
    RNA Biol; 2017 Mar; 14(3):378-388. PubMed ID: 28145797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arginine CGA codons as a source of nonsense mutations: a possible role in multivariant gene expression, control of mRNA quality, and aging.
    Romanov GA; Sukhoverov VS
    Mol Genet Genomics; 2017 Oct; 292(5):1013-1026. PubMed ID: 28523359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development.
    Rowe SM; Clancy JP
    BioDrugs; 2009; 23(3):165-74. PubMed ID: 19627168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations.
    Nudelman I; Glikin D; Smolkin B; Hainrichson M; Belakhov V; Baasov T
    Bioorg Med Chem; 2010 Jun; 18(11):3735-46. PubMed ID: 20409719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Limited premature termination codon suppression by read-through agents in cystic fibrosis intestinal organoids.
    Zomer-van Ommen DD; Vijftigschild LA; Kruisselbrink E; Vonk AM; Dekkers JF; Janssens HM; de Winter-de Groot KM; van der Ent CK; Beekman JM
    J Cyst Fibros; 2016 Mar; 15(2):158-62. PubMed ID: 26255232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A flow cytometry-based reporter assay identifies macrolide antibiotics as nonsense mutation read-through agents.
    Caspi M; Firsow A; Rajkumar R; Skalka N; Moshkovitz I; Munitz A; Pasmanik-Chor M; Greif H; Megido D; Kariv R; Rosenberg DW; Rosin-Arbesfeld R
    J Mol Med (Berl); 2016 Apr; 94(4):469-82. PubMed ID: 26620677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives.
    Pibiri I; Lentini L; Melfi R; Gallucci G; Pace A; Spinello A; Barone G; Di Leonardo A
    Eur J Med Chem; 2015 Aug; 101():236-44. PubMed ID: 26142488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglycoside-induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy.
    Zingman LV; Park S; Olson TM; Alekseev AE; Terzic A
    Clin Pharmacol Ther; 2007 Jan; 81(1):99-103. PubMed ID: 17186006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs).
    Nagel-Wolfrum K; Möller F; Penner I; Baasov T; Wolfrum U
    BioDrugs; 2016 Apr; 30(2):49-74. PubMed ID: 26886021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of APC gene function in colorectal cancer cells by aminoglycoside- and macrolide-induced read-through of premature termination codons.
    Zilberberg A; Lahav L; Rosin-Arbesfeld R
    Gut; 2010 Apr; 59(4):496-507. PubMed ID: 19951906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.
    Linde L; Boelz S; Nissim-Rafinia M; Oren YS; Wilschanski M; Yaacov Y; Virgilis D; Neu-Yilik G; Kulozik AE; Kerem E; Kerem B
    J Clin Invest; 2007 Mar; 117(3):683-92. PubMed ID: 17290305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimized approach for the identification of highly efficient correctors of nonsense mutations in human diseases.
    Benhabiles H; Gonzalez-Hilarion S; Amand S; Bailly C; Prévotat A; Reix P; Hubert D; Adriaenssens E; Rebuffat S; Tulasne D; Lejeune F
    PLoS One; 2017; 12(11):e0187930. PubMed ID: 29131862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binary specification of nonsense codons by splicing and cytoplasmic translation.
    Thermann R; Neu-Yilik G; Deters A; Frede U; Wehr K; Hagemeier C; Hentze MW; Kulozik AE
    EMBO J; 1998 Jun; 17(12):3484-94. PubMed ID: 9628884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.